The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

In patients showing cognitive decline, a new blood test for Alzheimer's is expected to make diagnosis more convenient, ...

The FDA cleared the first blood test on Friday to help diagnose Alzheimer's disease among older Americans already exhibiting signs and symptoms of the condition.

The Lumipulse test has specifically been approved to help diagnose the disease in the clinical setting. Dr. Amanada Smith ...

It’s got quite the name. The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients, aged 55 years ...

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first blood test aiding Alzheimer's diagnosis by detecting amyloid plaques, offering a less invasive alternative to PET scans.

The FDA has cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood test for early Alzheimer's detection in adults aged 55 and older showing symptoms. It analyzes ...

NewAmsterdam Pharma has said that an oral drug it is developing to lower cholesterol has shown preliminary efficacy as a ...

Its mouthful of a name — Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio — describes what the test measures: levels of two proteins, amyloid and tau, that are hallmarks of Alzheimer’s disease.

LH's growth focus and financial strength look promising, but can it navigate rising competition and macro headwinds?

Fujirebio’s Lumipulse G pTau217/ -Amyloid 1-42 Plasma Ratio was developed for the early detection of amyloid plaques associated with AD in adults aged 55 years and older who show signs of the ...

The test is called the “Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio” and is developed by the Japanese company Fujirebio Diagnostics Inc. It measures specific biomarkers and proteins ...